Silencing Investor Concerns? Alnylam Achieves RNAi Milestone
News Aug 01, 2012
While almost all other viral vaccines (e.g., mumps, measles, and polio) are currently produced via cell-culture, influenza vaccines have been resistant to cell-culture based manufacturing due to insufficient virus yield and quality. GSK hopes to utilize Alnylam’s VaxiRNA platform to overcome these challenges. The proprietary VaxiRNA technology utilizes RNAi to silence genes that limit or prevent the production of vaccine antigens.
As part of the collaboration, which was initiated in the fourth quarter of 2011, Alnylam receives R&D funding and milestone payments from GSK as well as royalties from any commercialized vaccine. GSK hopes to capitalize on Alnylam’s expertise to generate a commercially viable cell-culture based influenza vaccine that could be first to market in the United States.
The development of an innovative method to produce influenza vaccines has become a major initiative. Since the 1940s, influenza vaccines have been generated using chicken eggs. This process takes months and is difficult to scale-up. The recent H1N1 influenza pandemic highlighted these inadequacies and resulted in a renewed push for novel influenza vaccine manufacturing methodologies. A novel production process could also generate a vaccine that could be administered to individuals with egg allergies and decrease overall manufacturing costs. GSK expects to utilize its cell-culture method to enter this emerging market, but the company faces tough competition. For example, Novartis, in collaboration with the United States Department of Health and Human Services, is building a $1 billion facility in North Carolina that will house R&D and production facilities for a cell-culture based influenza vaccine program.
The milestone payment comes during a challenging time for Alnylam. Its ambitious “5x15” program hopes to develop RNAi therapies for five diseases with a high unmet need (e.g., hemophilia, hypercholesterolemia, refractory anemia) by 2015. Earlier this month, the company announced positive Phase I results concerning its therapy for transthyretin (TTR) amyloidosis, a progressive neurodegenerative disease caused by protein deposits, as well as promising pre-clinical results for its hemophilia treatment. These findings raised Alnylam’s stock price over 150% to $18.76 per share, but a pending lawsuit could cause shareholders to worry. Tekmira Pharmaceuticals Corporation, a Vancouver-based biotechnology company, alleges that Alnylam exploited their collaboration for commercial gain. The patent litigation, which heads to trial in October, threatens to hinder Alnylam’s ability to commercialize its 5x15 initiative. Alnylam is especially susceptible to any delay in 5x15-associated revenue since it has no marketed therapies. While Alnylam possibly struggles to transition from commercial platforms to therapies, a successful influenza vaccine methodology could alleviate investor concerns in the short-term.
First Successful Gene Therapy Trial Reported for People with Hemophilia ANews
Patients with hemophilia A who received a single infusion of an investigational gene therapy showed improved levels of the essential blood clotting protein FVIII, with 11 of 13 achieving normal or near-normal FVIII levels.READ MORE
Some Immune Cells May Help Tumors Instead of Destroying ThemNews
New data shows that neutrophils promote tumor progression and can actually hamper the work of immunotherapy in lung cancer.READ MORE
Oligonucleotide Drug Producers Report on Drug ImpuritiesNews
A new addition to a series of articles that focus on important topics related to the development of oligonucleotide therapeutics presents an in-depth look at the identification, characterization, and reporting of product-related impurities.READ MORE